Market revenue in 2023 | USD 90.7 million |
Market revenue in 2030 | USD 172.2 million |
Growth rate | 9.6% (CAGR from 2023 to 2030) |
Largest segment | Pharmaceuticals |
Fastest growing segment | Devices |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Devices |
Key market players worldwide | Johnson & Johnson, Cipla Ltd DR, Sun Pharmaceutical Industries, Merck & Co Inc, Dr. Reddy’s Laboratories, Cardiff Lexington Corp, Amgen Inc, Theradome, Aurobindo Pharma, Curallux, Apira Science |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to androgenetic alopecia market will help companies and investors design strategic landscapes.
Pharmaceuticals was the largest segment with a revenue share of 96.47% in 2023. Horizon Databook has segmented the Canada androgenetic alopecia market based on pharmaceuticals, devices covering the revenue growth of each sub-segment from 2018 to 2030.
The androgenetic alopecia market in Canada is anticipated to witness significant growth over the forecast period due to research collaborations and strong product pipelines of local players.
For instance, in June 2023, Triple Hair Group Inc. received the No Objection Letter from Health Canada to initiate a phase 3 clinical study for an innovative triple combination therapy, Therapy-07, which has the potential to promote hair regrowth in men with androgenetic alopecia.
In addition, in October 2021, RepliCel Life Sciences, another Canada-based biotech company, collaborated with Shiseido Company to develop autologous cell therapy RCH-01, which treats AGA by using dermal sheath cup cells separated from the hair follicle. Currently, this product is undergoing a phase 3 clinical trial.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada androgenetic alopecia market , including forecasts for subscribers. This country databook contains high-level insights into Canada androgenetic alopecia market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account